CYTR CytRx Corporation

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of CytRx Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 23, 2016 – CYTR

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) between November 18, 2014 and July 11, 2016.

You are hereby notified that a securities class action has commenced in the USDC for the Central District of California. If you purchased or otherwise acquired CytRx securities between November 18, 2014 and July 11, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/cytrx-corporation.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts including: (1) that the clinical hold placed on the Phase 3 trial of aldoxorubicin for soft tissue sarcomas (“STSs”) would prevent sufficient follow-up for patients involved in the study; (2) that, as a result, nearly half of all patients would be excluded from the data since the study was disturbed by a partial clinical hold; (3) that, in response, CytRx would likely conduct a second analysis; (4) and that the results of the trial could be materially affected and/or approval of aldoxorubicin for STS could be delayed.

If you suffered a loss in CytRx you have until September 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/cytrx-corporation.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

30 Broad Street - 24th Floor

New York, NY 10004

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

EN
09/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytRx Corporation

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: August 20, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MarketLine Department
  • MarketLine Department

CytRx Corporation – Mergers & Acquisitions (M&A), Partnerships & All...

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights United States

Insider bought: A director bought 2,325,581 shares at 0.430USD and

A director at Cytrx Corp bought 2,325,581 shares at 0.430USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

 PRESS RELEASE

24-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investo...

BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired CytRx Corporation (“CytRx” or the “Company”) (NASDAQ: CYTR) securities between November 18, 2014 and July 11, 2016, inclusive (the “Class Period”). CytRx investors have until September 23, 2016 to file a lead plaintiff motion. The Complaint alleges that throughout the Class Perio...

 PRESS RELEASE

GPM Reminds Investors of the September 23rd Deadline in the Class Acti...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired CytRx Corporation (“CytRx” or the “Company”) (NASDAQ: CYTR) securities between November 18, 2014 and July 11, 2016, inclusive (the “Class Period”). CytRx investors have until September 23, 2016 to file a lead plaintiff motion. The Complaint alleges that throughout the Class Peri...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch